Andreas Struengmann built enormous additional value through Hexal and later biotech investing, but he began from the same meaningful family pharmaceutical business platform as his twin brother Thomas. [1][2]
The brothers entered business through their father's company
Bloomberg's account of the Struengmann family says Andreas and Thomas joined their father Ernst's pharmaceutical company, Durachemie, in 1979 before creating their later generic-drug business. [2]
That family enterprise supplied both operating experience and meaningful capital, so Andreas did not begin from the same financial position as a founder relying only on personal savings or modest seed funding. [2]
Forbes says Andreas and Thomas co-founded Hexal in 1986 and sold the generic-drug maker to Novartis in 2005 for about $7 billion, producing value far beyond the original family platform. [1]
Biotech investments created a second major source of value
Forbes says the brothers were early backers of BioNTech and continue to invest across biotech, pharmaceuticals, life sciences and healthcare through their jointly controlled investment structure. [1]
The reviewed evidence supports substantial self-created scale alongside a meaningful inherited advantage, placing Andreas between a classic inherited-business expansion case and a primarily self-created fortune. [1][2]
Sources for background
Sources reviewed Sep 22, 2026.
- Andreas Struengmann & family · Forbes · Mar 10, 2026
- Bloomberg Billionaires Index - Thomas Struengmann · Bloomberg · May 13, 2026
Comparable Healthcare billionaires
Similar Healthcare billionaires by estimated net worth.
%20cropped.jpg?width=512)
